Although genetic screening plus surveillance for children with certain genetic variants could reduce cancer deaths by 7.8 percent before age 20, health systems may not find such programs cost effective.
The Phase I/II study results suggest Retevmo may benefit patients with any tumor type that has RET fusions and could support a tissue-agnostic indication.
The company is testing the RAF/MEK inhibitor and FAK inhibitor combination in a randomized study after promising Phase I data presented at AACR.
The Phase III trial evaluated tebentafusp in patients with HLA-A*02:01-positive metastatic uveal melanoma compared to Keytruda, Yervoy, or chemo.
Based on results from a pilot study, Dutch lawmakers are advancing a proposal to make WGS a standard test for advanced cancer patients.
The group is setting aside 5 percent of its annual test volume for the underserved and is hoping to partner with pharma and other groups to grow the program.
The firm's BRAF inhibitor, PLX8394, targets cancers with non-V600 BRAF mutations that see little benefit from BRAF inhibitors currently on the market.
The company was cleared to begin a Phase I/II trial of its lead candidate, a therapeutic vaccine that can potentially treat and prevent recurrence of KRAS-mutated cancers.
The firm will begin a 100,000-patient study of its investigational liquid biopsy assay that could help bring targeted therapies into earlier lines of treatment.
In a recently published study, researchers found NTRK fusions were more common in pediatric than adult tumors and testing for them helped diagnose rare tumors.